Lexington, MA-based Agenus has bagged the rights to some cancer-related antibodies from Italy's Diatheva s.r.l., agreeing to fork over up to $44 million in milestones for a successful development program. These antibodies target carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), a glycoprotein expressed on T cell and NK cell lymphocytes. CEACAM1 is overexpressed in melanoma, bladder, lung, colon, pancreas, and gastric cancers and has been studied in preclinical work which has illustrated an ability to "modulate innate and adaptive immune suppression." Release